15 sep 25   crystal amber fund - morphic medical inc. appoints new cfo crystal amber fund ltd. | crs | 0 0 0.0% | mkt cap: 52.9m    rns number : 3025z crystal amber fund limited 15 september 2025   reach - a non-regulatory announcement 15 september 2025   crystal amber fund limited ("crystal amber fund", the "company" or the "fund")   morphic medical inc. appoints new chief financial officer   the board of crystal amber fund is pleased to see the announcement by morphic medical inc. ("morphic medical"), the medical device company that has pioneered minimally invasive treatments of obesity and cardiometabolic disorders in which it owns 96.7% of the issued share capital, that it has appointed jane wright as its chief financial officer.   jane is a qualified accountant with over 30 years of experience including several senior financial and operational positions in international medical device companies, navigating complex regulatory environments and driving strategic growth and operational efficiency.   prior to joining morphic medical, she served as finance & operations director at apollo endosurgery,  a specialist in endoluminal surgery (els) procedures which was acquired by boston scientific corporation in 2022.   jane's arrival follows the appointment of mike gutteridge as chief executive officer in july and marks the latest milestone for the morphic medical business.   following recent ce mark certification and commercial registration by the uk's mhra, reset® is cleared for sale across key european markets, including germany where rollout has already begun. in her new role, wright will play a key role in shaping the company's long-term financial strategy and supporting its continued growth.   research presented to the ifso world congress of obesity experts this month has shown that reset® delivers substantial and durable benefits, with patients losing an average of 18.9% of their total body weight, while also improving blood sugar control.   christopher waldron, chairman of crystal amber, commented: "we are pleased to see morphic medical strengthening its executive team as the momentum within the business continues to build."     for further enquiries please contact:   crystal amber fund limited chris waldron (chairman) tel: 01481 742 742 www.crystalamber.com   allenby capital limited - nominated adviser jeremy porter/ dan dearden-williams tel: 020 3328 5656   winterflood investment trusts - broker joe winkley/neil langford tel: 020 3100 0160   crystal amber advisers (uk) llp - investment adviser richard bernstein tel: 020 7478 9080   about reach announcements this is a reach announcement. reach is an investor communication service aimed at assisting listed and unlisted (including aim quoted) companies to distribute media only / non-regulatory news releases into the public domain. information required to be notified under the aim rules for companies, market abuse regulation or other regulation would be disseminated as an rns regulatory announcement and not on reach.     this information is provided by reach, the non-regulatory press release distribution service of rns, part of the london stock exchange. terms and conditions relating to the use and distribution of this information may apply. for further information, please contact rns@lseg.com or visit www.rns.com.  rns may use your ip address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. for further information about how rns and the london stock exchange use the personal data you provide us, please see our privacy policy.   end   nravzlffeklfbbz return to news summary

Label: Gestiegen